J. Goldman & Co LP acquired a new stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 176,770 shares of the company's stock, valued at approximately $2,558,000. J. Goldman & Co LP owned 0.28% of Design Therapeutics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Torren Management LLC acquired a new stake in Design Therapeutics in the fourth quarter valued at approximately $26,000. State of Wyoming acquired a new position in shares of Design Therapeutics during the second quarter worth $37,000. Legal & General Group Plc acquired a new position in shares of Design Therapeutics during the second quarter worth $43,000. Russell Investments Group Ltd. boosted its stake in shares of Design Therapeutics by 69.6% in the third quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company's stock valued at $48,000 after purchasing an additional 2,618 shares during the period. Finally, Invesco Ltd. grew its holdings in Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after purchasing an additional 3,033 shares in the last quarter. Institutional investors and hedge funds own 56.64% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently issued reports on DSGN shares. Oppenheimer lifted their price target on shares of Design Therapeutics from $18.00 to $21.00 and gave the stock an "outperform" rating in a research note on Monday, May 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Design Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded Design Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, May 10th. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 target price on shares of Design Therapeutics in a research report on Wednesday, April 29th. Finally, Cantor Fitzgerald assumed coverage on Design Therapeutics in a research note on Tuesday, May 12th. They issued an "overweight" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $16.50.
View Our Latest Stock Report on DSGN
Design Therapeutics Stock Performance
Shares of Design Therapeutics stock opened at $15.68 on Wednesday. Design Therapeutics, Inc. has a 1 year low of $4.92 and a 1 year high of $17.25. The firm's 50-day simple moving average is $13.77 and its 200-day simple moving average is $12.25. The firm has a market cap of $981.25 million, a PE ratio of -13.29 and a beta of 1.63.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.02. On average, equities analysts predict that Design Therapeutics, Inc. will post -1.41 earnings per share for the current year.
Design Therapeutics Company Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
